The identification of the mobile receptor utilized by viruses to enter their goal cells is all the time a problem and so far entry receptors stay to be recognized for quite a lot of pathogenic human viruses. Human T-lymphotropic virus sort 1 (HTLV-1), the distinctive oncogenic retrovirus in human, was recognized within the early 1980 ‘s.
The character of its entry receptor has remained a thriller for over 20 years, till the unbiased identification of three proteins presenting the anticipated standards, the glucose transporter Glut1, Neuropilin 1, a VEGF receptor, and heparan sulfate proteoglycans. On this overview, we summarize the information pertaining to HTLV-1 entry molecules and current a brand new mannequin, during which these three proteins successively intervene in the course of the entry course of.
Protecting efficacy of rhesus adenovirus COVID-19 vaccines in opposition to mouse-adapted SARS-CoV-2
The speedy design and implementation of extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is testomony to a efficiently coordinated international analysis effort. Whereas using quite a lot of totally different applied sciences, a few of which have been used for the primary time, all authorized vaccines show excessive ranges of efficacy with glorious security profiles.
Regardless of this, there stays an pressing international demand for coronavirus illness 2019 vaccines that require additional candidates to move part three medical trials. Within the expectation of SARS-CoV-2 changing into endemic, researchers want to alter the vaccine constructs to sort out rising variants.
On this overview, we define totally different platforms used for authorized vaccines and summarize newest analysis information close to immunogenicity, dosing regimens and effectivity in opposition to rising variants.

A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 An infection and Its Utility in a Inhabitants-Primarily based Survey by Mail
Noninvasive salivary antibody immunoassays can allow low-cost epidemiological surveillance of infections. This research concerned growing and validating a multiplex suspension immunoassay on the Luminex platform to measure immunoglobulin G (IgG) responses to extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid and spike (S) proteins, and the spike protein’s S1 and S2 subunits and receptor binding area.
A number of variations of those recombinant proteins acquired from industrial and noncommercial sources have been evaluated. Assay improvement and validation utilized saliva and serum samples from coronavirus illness 2019 (COVID-19) circumstances procured from industrial sources and adverse controls from a prepandemic survey.
Saliva was additionally collected in an indication survey by mail involving grownup people in america who have been recognized with SARS-CoV-2 an infection 15 to 80 days previous to pattern assortment. The survey had an 83% legitimate pattern return price (192 samples from 38 states). Most COVID-19 circumstances (93%) reported mildly symptomatic or asymptomatic infections.
The ultimate salivary assay based mostly on the best-performing spike and nucleocapsid proteins had a sensitivity of 87.1% (95% bootstrap confidence interval, 82.1 to 91.7%) and specificity of 98.5% (95.Zero to 100%) utilizing 227 and 285 saliva samples, respectively.
The identical assay had 95.9% (92.eight to 98.9%) sensitivity and 100% (98.four to 100%) specificity in serum (174 and 285 serum samples, respectively). Salivary and serum antibody responses to spike and nucleocapsid proteins have been strongly correlated in 22 paired samples (r = 0.88 and r = 0.80, respectively).
Antibody responses peaked at roughly 50 days postonset; better sickness severity was related to stronger responses. This research demonstrated {that a} salivary antibody assay can be utilized in large-scale inhabitants surveys by mail to raised characterize public well being impacts of COVID-19. IMPORTANCE Given the large impacts of the COVID-19 pandemic, growing instruments for inhabitants surveillance of an infection is of paramount significance.
This text describes the event of a multiplex immunoassay on a Luminex platform to measure salivary immunoglobulin G responses to the spike protein, its two subunits and receptor binding area, and the nucleocapsid protein of SARS-CoV-2. The assay validation utilized serum and saliva samples from prepandemic controls and up to date COVID-19 circumstances.
A survey by mail focusing on latest COVID-19 circumstances throughout america additionally demonstrated the utility of protected, at-home self-collection of saliva. By incorporating a number of SARS-CoV-2 proteins, this assay might differentiate responses to pure SARS-CoV-2 infections from responses to most vaccines.
Utility of this noninvasive immunoassay in COVID-19 surveillance can assist present estimates of cumulative incidence charges of symptomatic and asymptomatic infections in numerous communities and subpopulations, temporal patterns of antibody responses, and threat components for an infection.
Uncared for roles of IgG Fc-binding protein secreted from airway mucin-producing cells in defending in opposition to SARS-CoV-2 an infection
Each innate immunity and purchased immunity are concerned in extreme acute respiratory syndrome coronavirus-2 (SARS-CoV-2) an infection. The induction of Abs that neutralize the virus has been described, and sure Abs in opposition to endemic coronaviruses might cross-react with SARS-CoV-2. Detailed mechanisms to guard in opposition to the pandemic of SARS-CoV-2 stay unresolved.
We beforehand reported that IgG Fc-binding protein (Fcγbp), a novel, massive molecular weight, and mucin-like secretory Fc receptor protein, secreted from goblet cells of human small and enormous gut, mediates the transportation of serum IgG onto the mucosal floor.
On this overview, we present that mucous bronchial gland cells and a few goblet cells are immunoreactive for Fcγbp. Fcγbp traps the cross-reactive (each neutralizing and non-neutralizing) IgG certain to the virus and may consequently remove the virus from the mucosal floor to lower viral hundreds.
Fcγbp may suppress immune overreaction by interfering with Fc-binding by macrophages and competing with complement fixation. Fcγbp secreted from mucin-producing cells of the airway capabilities as an necessary anti-infection mucosal protection. The Fcγbp-mediated mechanism could be a key think about explaining why SARS-CoV-2 is much less infective/deadly in youngsters, and may be concerned within the distinctive Ab response, recurrent an infection, and results of serum remedy and vaccination.
Protecting efficacy of rhesus adenovirus COVID-19 vaccines in opposition to mouse-adapted SARS-CoV-2
The worldwide COVID-19 pandemic has sparked intense curiosity within the speedy improvement of vaccines in addition to animal fashions to guage vaccine candidates and to outline immune correlates of safety. We lately reported a mouse-adapted SARS-CoV-2 virus pressure (MA10) with the potential to contaminate wild-type laboratory mice, driving excessive ranges of viral replication in respiratory tract tissues in addition to extreme medical and respiratory signs, points of COVID-19 illness in people which are necessary to seize in mannequin techniques.
We evaluated the immunogenicity and protecting efficacy of novel rhesus adenovirus serotype 52 (RhAd52) vaccines in opposition to MA10 problem in mice. Baseline seroprevalence is decrease for rhesus adenovirus vectors than for human or chimpanzee adenovirus vectors, making these vectors enticing candidates for vaccine improvement.
We noticed that RhAd52 vaccines elicited sturdy binding and neutralizing antibody titers, which inversely correlated with viral replication after problem. These information help the event of RhAd52 vaccines and the usage of the MA10 problem virus to display screen novel vaccine candidates and to review the immunologic mechanisms that underscore safety from SARS-CoV-2 problem in wild-type mice.
Significance We have now developed a sequence of SARS-CoV-2 vaccines utilizing rhesus adenovirus serotype 52 (RhAd52) vectors, which reveals a decrease seroprevalence than human and chimpanzee vectors, supporting their improvement as novel vaccine vectors or in its place Advert vector for enhancing.
We sought to check these vaccines utilizing a lately reported mouse-adapted SARS-CoV-2 (MA10) virus to i) consider the protecting efficacy of RhAd52 vaccines and ii) additional characterize this mouse-adapted problem mannequin and probe immune correlates of safety.
Recombinant SARS SARS Mosaic S(C) Protein, Untagged, E.coli-100ug |
QP13420-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Mosaic S(C) Protein, Untagged, E.coli-500ug |
QP13420-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
Recombinant SARS SARS Mosaic S(M) Protein, Untagged, E.coli-100ug |
QP13421-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Mosaic S(M) Protein, Untagged, E.coli-500ug |
QP13421-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
Recombinant SARS SARS Mosaic S(N) Protein, Untagged, E.coli-100ug |
QP13422-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Mosaic S(N) Protein, Untagged, E.coli-500ug |
QP13422-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
Recombinant SARS S Protein (aa 1-1190) [His] |
VAng-Lsx0060-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: SARS Surface Antigen (aa 1-1190) [His], recombinant protein from HEK 293 cells. |
SARS Associated Spike Mosaic S Protein |
20-abx260156 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1646.40
|
|
|
SARS-CoV-2 Antibody (NSP1 / Leader protein) |
RQ6298 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV-2 N Protein Monoclonal Antibody |
A73663 |
EpiGentek |
|
|
SARS Associated Spike Mosaic S(M) Protein |
20-abx260155 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1646.40
|
|
|
SARS Associated Spike Mosaic S(N) Protein |
20-abx260157 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1646.40
|
|
|
SARS-CoV-2 Nucleocapsid Protein Antibody (2019-nCov) |
R20435-100UG |
NSJ Bioreagents |
100ug |
EUR 409 |
SARS-CoV-2 Spike RBD protein antibody pair 1 |
CSB-EAP33245 |
Cusabio |
1 pair |
EUR 900 |
|
Description: This is a set of capture antibody and HRP-conjugated antbody for quantitative detection of SARS-CoV-2 Spike RBD protein for through solid phase sandwich ELISA. |
SARS antibody |
39139-100ul |
SAB |
100ul |
EUR 302.4 |
SARS antibody |
70R-1444 |
Fitzgerald |
100 ug |
EUR 452.4 |
Description: Rabbit polyclonal SARS antibody raised against the C terminal of SARS |
SARS antibody |
70R-1445 |
Fitzgerald |
100 ug |
EUR 452.4 |
Description: Rabbit polyclonal SARS antibody raised against the middle region of SARS |
SARS antibody |
70R-20086 |
Fitzgerald |
50 ul |
EUR 522 |
Description: Rabbit polyclonal SARS antibody |
SARS Antibody |
1-CSB-PA04145A0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200 |
SARS Antibody |
1-CSB-PA020709GA01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
SARS-CoV-2 S Recombinant Antibody, HRP Conjugated |
A73673 |
EpiGentek |
|
|
SARS-CoV-2 S Recombinant Antibody, FITC Conjugated |
A73674 |
EpiGentek |
|
|
SARS-CoV S Recombinant Protein (R667A, K968P, V969P) |
11-115 |
ProSci |
0.1 mg |
EUR 884.4 |
Description: It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 S Recombinant Antibody, Biotin Conjugated |
A73675 |
EpiGentek |
|
|
Recombinant SARS Spike Mosaic Protein S (N-Terminal) |
VAng-Lsx0073-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: SARS spike mosaic protein S (N-terminal), recombinant protein from E. coli. |
SARS E2 antibody |
10R-1976 |
Fitzgerald |
100 ul |
EUR 289.2 |
Description: Mouse monoclonal SARS E2 antibody |
SARS M antibody |
10R-1977 |
Fitzgerald |
100 ul |
EUR 289.2 |
Description: Mouse monoclonal SARS M antibody |
SARS protein (His tag) |
80R-2099 |
Fitzgerald |
50 ug |
EUR 386.4 |
Description: Recombinant human SARS protein (His tag) |
SARS-M Antibody |
abx016056-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
anti- SARS antibody |
FNab07609 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against SARS |
SARS-CoV-2 (COVID-19) S Protein RBD Recombinant Protein |
10-433 |
ProSci |
0.1 mg |
EUR 714.3 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S Protein NTD Recombinant Protein |
92-738 |
ProSci |
0.05 mg |
EUR 468.6 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S Protein HR1 Recombinant Protein |
92-760 |
ProSci |
0.05 mg |
EUR 468.6 |
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. After binding of RBD in S1 subunit of S protein on the virion to the ACE2 receptor on the target cell, the heptad repeat 1 (HR1) and 2 (HR2) domains in its S2 subunit of S protein interact with each other to form a six-helix bundle (6-HB) fusion core, bringing viral and cellular membranes into close proximity for fusion and infection. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S Protein HR1 Recombinant Protein |
92-761 |
ProSci |
0.05 mg |
EUR 468.6 |
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. After binding of RBD in S1 subunit of S protein on the virion to the ACE2 receptor on the target cell, the heptad repeat 1 (HR1) and 2 (HR2) domains in its S2 subunit of S protein interact with each other to form a six-helix bundle (6-HB) fusion core, bringing viral and cellular membranes into close proximity for fusion and infection. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-E2 Antibody |
abx016055-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
SARS Spike Antibody |
20-abx137184 |
Abbexa |
-
EUR 1262.40
-
EUR 1846.80
-
EUR 2064.00
|
|
|
SARS Spike Antibody |
20-abx137200 |
Abbexa |
-
EUR 1412.40
-
EUR 2264.40
-
EUR 2665.20
|
|
|
SARS Spike Antibody |
24216-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24217-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24218-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24219-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
24318-100ul |
SAB |
100ul |
EUR 468 |
SARS-CoV-2 (COVID-19) S RBD Recombinant Protein |
10-413 |
ProSci |
0.1 mg |
EUR 714.3 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S RBD Recombinant Protein |
10-431 |
ProSci |
0.1 mg |
EUR 714.3 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S Recombinant Protein RBD |
11-215 |
ProSci |
0.2 mg |
EUR 1086 |
Description: It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S RBD Recombinant Protein |
97-093 |
ProSci |
0.1 mg |
EUR 714.3 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, DPP4, CEACAM etc.. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS Matrix Antibody |
24319-100ul |
SAB |
100ul |
EUR 468 |
SARS Matrix Antibody |
24320-100ul |
SAB |
100ul |
EUR 468 |
SARS Protein Detection Set |
PSI-1810 |
ProSci |
1 Set |
EUR 884.4 |
|
Description: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral S (Spike) protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. The M protein (Membrane protein, Matrix protein) is another major structural viral protein. It is an integral membrane protein involved in the budding of the viral particles and interacts with S protein and the nucleocapsid protein. The SARS E protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. ACE2, the SARS receptor, normally plays a central role in vascular, renal, and myocardial physiology. In contrast to its homolog ACE, ACE2 expression is restricted to heart, kidney, and testis.;;For images please see PDF data sheet |
Human Chimeric SARS-CoV-2 Nucleocapsid Protein Antibody (2019-nCov) |
R20480-100UG |
NSJ Bioreagents |
100ug |
EUR 409 |
SARS Envelope Antibody |
24321-100ul |
SAB |
100ul |
EUR 468 |
SARS Envelope Antibody |
24322-100ul |
SAB |
100ul |
EUR 468 |
SARS-CoV-2 (COVID-19) S-trimer Recombinant Protein |
11-070 |
ProSci |
0.1 mg |
EUR 695.4 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS Conjugated Antibody |
C39139 |
SAB |
100ul |
EUR 476.4 |
SARS Polyclonal Antibody |
A53977 |
EpiGentek |
-
EUR 684.66
-
EUR 117.70
-
EUR 302.50
-
EUR 423.50
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
SARS Coronavirus antibody |
10C-CR9003M1 |
Fitzgerald |
100 ug |
EUR 598.8 |
Description: Mouse monoclonal SARS Coronavirus antibody |
Recombinant Coronavirus Spike Protein (SARS-CoV S, His tag) |
P1520-10 |
Biovision |
10µg |
EUR 308.4 |
Recombinant SARS SARS MERS Protein, His, E.coli-1mg |
QP13419-1mg |
EnQuireBio |
1mg |
EUR 1513.2 |
SARS Nucleocapsid Antibody |
20-abx137185 |
Abbexa |
-
EUR 1262.40
-
EUR 1846.80
-
EUR 2364.00
|
|
|
SARS Nucleocapsid Antibody |
20-abx137201 |
Abbexa |
-
EUR 1412.40
-
EUR 2264.40
-
EUR 2665.20
|
|
|
SARS Nucleocapsid antibody |
10R-10470 |
Fitzgerald |
100 ug |
EUR 522 |
Description: Mouse monoclonal SARS Nucleocapsid antibody |
SARS Nucleocapsid antibody |
10R-10471 |
Fitzgerald |
100 ug |
EUR 522 |
Description: Mouse monoclonal SARS Nucleocapsid antibody |
Recombinant SARS SARS-CoV Protein, His, E.coli-1mg |
QP13423-1mg |
EnQuireBio |
1mg |
EUR 4744.8 |
Recombinant SARS SARS-CoV Protein, His, E.coli-5ug |
QP13423-5ug |
EnQuireBio |
5ug |
EUR 186 |
Recombinant SARS SARS MERS Protein, His, E.coli-100ug |
QP13419-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS MERS Protein, His, E.coli-500ug |
QP13419-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
Recombinant SARS SARS-CoV Protein, His, E.coli-20ug |
QP13423-20ug |
EnQuireBio |
20ug |
EUR 241.2 |
SARS-CoV-2 (COVID-19) S + M + E Recombinant Protein |
11-071 |
ProSci |
0.1 mg |
EUR 695.4 |
Description: Coronavirus envelope (E) proteins are short (100 residues) polypeptides that contain at least one transmembrane (TM) domain and a cluster of 2-3 juxtamembrane cysteines. These proteins are involved in viral morphogenesis and tropism, and their absence leads in some cases to aberrant virions, or to viral attenuation. In common to other viroporins, coronavirus envelope proteins increase membrane permeability to ions, plays a central role in virus morphogenesis and assembly. Acts as a viroporin and self-assembles in host membranes forming pentameric protein-lipid pores that allow ion transport. Also plays a role in the induction of apoptosis. Activates the host NLRP3 inflammasome, leading to IL-1beta overproduction. |
SARS-CoV-2 (COVID-19) S Protein RBD-SD1 Recombinant Protein |
92-736 |
ProSci |
0.05 mg |
EUR 468.6 |
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S Protein RBD-SD1 Recombinant Protein |
92-737 |
ProSci |
0.02 mg |
EUR 556.8 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S Protein RBD (N501Y) Recombinant Protein |
92-762 |
ProSci |
0.05 mg |
EUR 569.4 |
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S Protein RBD (N501Y) Recombinant Protein |
92-763 |
ProSci |
0.05 mg |
EUR 569.4 |
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
Recombinant SARS SARS Core Protein, Untagged, E.coli-1mg |
QP13416-1mg |
EnQuireBio |
1mg |
EUR 1273.2 |
Recombinant SARS SARS Core Protein, Untagged, E.coli-1mg |
QP10499-1mg |
EnQuireBio |
1mg |
EUR 1273.2 |
Recombinant SARS Spike Mosaic S Protein (aa 408-470, 540-573) |
VAng-Lsx0056-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Recombinant SARS-CoV Spike protein containing 408-470, 540-573 amino acids immunodominant regions was expressed in E. coli and purified by proprietary chromatographic technique. |
SARS virus Sn Antibody |
abx032683-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
SARS virus Sn Antibody |
abx032683-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
SARS virus Sm Antibody |
abx032684-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
SARS virus Sm Antibody |
abx032684-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Recombinant SARS SARS Core Protein, Untagged, E.coli-100ug |
QP13416-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Core Protein, Untagged, E.coli-500ug |
QP13416-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
Recombinant SARS SARS Matrix Protein, Untagged, E.coli-1mg |
QP13418-1mg |
EnQuireBio |
1mg |
EUR 1273.2 |
Recombinant SARS SARS Core Protein, Untagged, E.coli-100ug |
QP10499-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Core Protein, Untagged, E.coli-500ug |
QP10499-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
SARS CoV E Protein |
abx060650-1mg |
Abbexa |
1 mg |
EUR 2030.4 |
|
Recombinant SARS SARS Envelope Protein, Untagged, E.coli-1mg |
QP13417-1mg |
EnQuireBio |
1mg |
EUR 1273.2 |
Recombinant SARS SARS Matrix Protein, Untagged, E.coli-100ug |
QP13418-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Matrix Protein, Untagged, E.coli-500ug |
QP13418-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
SARS-CoV-2 (COVID-19) S-trimer 6P Recombinant Protein |
11-068 |
ProSci |
0.1 mg |
EUR 714.3 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
Recombinant SARS S1 Protein [His] |
VAng-Lsx0061-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: SARS S1 [His], recombinant protein from E. coli. |
Recombinant SARS S2 Protein [His] |
VAng-Lsx0062-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: SARS S2 [His], recombinant protein from E. coli. |
Recombinant SARS SARS Envelope Protein, Untagged, E.coli-100ug |
QP13417-100ug |
EnQuireBio |
100ug |
EUR 261.6 |
Recombinant SARS SARS Envelope Protein, Untagged, E.coli-500ug |
QP13417-500ug |
EnQuireBio |
500ug |
EUR 795.6 |
PLPro Antibody (SARS-CoV) |
100863 |
BPS Bioscience |
250 µg |
EUR 360 |
Description: Chicken polyclonal antibody recognizing the SARS-CoV Papain-like Protease (PLpro) as a 35 kDa protein. Purified from egg yolks. This antibody recognizes PLPro from both SARS-CoV-1 and SARS-CoV-2. Does not cross react with SARS-CoV 3CL protease. |
SARS-CoV Spike Antibody |
3219-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3219-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3225-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3225-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV-2 (COVID-19) Spike S Trimer Recombinant Protein |
20-182 |
ProSci |
0.1 mg |
EUR 651.3 |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S-trimer (D614G) Recombinant Protein |
92-748 |
ProSci |
0.05 mg |
EUR 619.8 |
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell atthe advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acuterespiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusionrequired for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's beenreported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the humanACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor.S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction ofneutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV Matrix Antibody |
3527-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
3527-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
3529-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
3529-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV-2 (COVID-19) Trimeric Spike (S) Recombinant Protein |
10-075 |
ProSci |
0.1 mg |
EUR 991.5 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). The CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. Although both SARS-CoV and SARS-CoV-2 bind the ACE2 receptor, the RBDs only share ~73% amino acid identity, and the SARS-CoV-2 RBD binds with a higher affinity compared to SARS-CoV 3, 6. The RBD is dynamic and undergoes hinge-like conformational changes, referred to as the “down” or “up” conformations, which hide or expose the receptor-binding motifs, respectively 7. Following receptor binding, S1 destabilizes, and TMPRSS2 cleaves S2, which undergoes a pre- to post-fusion conformation transition, allowing for membrane fusion 8, 9. The S protein has been the main focus of therapeutic and vaccine design as it is highly immunogenic. Both neutralizing antibodies 10,11 and memory T cells 12,13 targeting the S protein are present in the sera of convalescent COVID-19 patients. |
ACE2 (SARS Receptor) Antibody |
abx032686-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
ACE2 (SARS Receptor) Antibody |
abx032686-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
SARS-CoV Spike Protein |
abx060655-1mg |
Abbexa |
1 mg |
EUR 2030.4 |
|
SARS-CoV Envelope Antibody |
3533-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
SARS-CoV Envelope Antibody |
3533-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
SARS Antibody, HRP conjugated |
1-CSB-PA04145B0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
SARS Antibody, FITC conjugated |
1-CSB-PA04145C0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
Polyclonal SARS Matrix Antibody |
APR11178G |
Leading Biology |
0.1 mg |
EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SARS Matrix . This antibody is tested and proven to work in the following applications: |
Polyclonal SARS Matrix Antibody |
APG02976G |
Leading Biology |
0.1 mg |
EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SARS Matrix . This antibody is tested and proven to work in the following applications: |
SARS Antibody, Biotin conjugated |
1-CSB-PA04145D0Rb |
Cusabio |
|
|
|
Description: A polyclonal antibody against SARS. Recognizes SARS from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
SARS Recombinant Protein (Rat) |
RP227480 |
ABM |
100 ug |
Ask for price |
SARS CoV Nucleocapsid Protein |
abx060652-1mg |
Abbexa |
1 mg |
EUR 2247.6 |
|
SARS Recombinant Protein (Mouse) |
RP170009 |
ABM |
100 ug |
Ask for price |
SARS Recombinant Protein (Mouse) |
RP170012 |
ABM |
100 ug |
Ask for price |
SARS Recombinant Protein (Human) |
RP027604 |
ABM |
100 ug |
Ask for price |
SARS Recombinant Protein (Human) |
RP027607 |
ABM |
100 ug |
Ask for price |
SARS-CoV-2 Antibody (ORF8) |
RQ6296 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF8 encodes a viral accessory protein. |
SARS-CoV-2 Antibody (NSP2) |
RQ6299 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV-2 Antibody (NSP3) |
RQ6300 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined. ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV-2 Antibody (NSP4) |
RQ6301 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV-2 Antibody (NSP7) |
RQ6302 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV-2 Antibody (NSP8) |
RQ6303 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV-2 Antibody (NSP9) |
RQ6304 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS-CoV Nucleocapsid Protein |
abx060653-1mg |
Abbexa |
1 mg |
EUR 2030.4 |
|
SARS-CoV Nucleocapsid Protein |
abx060654-1mg |
Abbexa |
1 mg |
EUR 2030.4 |
|
Recombinant SARS Matrix Protein |
VAng-Lsx0059-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: SARS Matrix, recombinant protein from E. coli. |
Recombinant SARS Spike Mosaic S Protein (aa 12-53, 90-115, 171-203) |
VAng-Lsx0055-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Recombinant SARS-CoV Spike protein containing 12-53, 90-115, 171-203 amino acids immunodominant regions was expressed in E. coli and purified by proprietary chromatographic technique. |
Recombinant SARS Spike Mosaic S Protein (aa 1051-1076, 1121-1154, 1162-1190) |
VAng-Lsx0057-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Recombinant SARS-CoV Spike protein containing 1051-1076, 1121-1154, 1162-1190 amino acids immunodominant regions was expressed in E. coli and purified by proprietary chromatographic technique. |
Recombinant SARS E Protein (aa 340-390) |
VAng-Lsx0069-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: SARS E Antigen (aa 340-390), recombinant protein from E. coli. |
SARS-CoV-2 Antibody (ORF3a) |
RQ6295 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined. ORF3a encodes a viral accessory protein. Based on its similarity to other coronavirus proteins, ORF3a protein is thought to be a protein with ion channel activity (viroporin) that activates the NLRP3 inflammasome. ORF3a may also play a role in virus replication and pathogenesis. |
SARS-CoV-2 Antibody (NSP10) |
RQ6305 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
Recombinant SARS E Protein (aa 1-76) |
VAng-Lsx0066-100g |
Creative Biolabs |
100 µg |
EUR 712.8 |
Description: SARS Envelope protein (aa 1-76), recombinant protein from E. coli. |
Recombinant SARS N Protein (aa 1-49) |
VAng-Lsx0071-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: SARS N protein (aa 1-49), recombinant protein from E. coli. |
SARS-CoV-2 (COVID-19) S1+S2 ECD (S-ECD) Recombinant Protein |
10-108 |
ProSci |
0.1 mg |
EUR 1186.8 |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity. |
SARS-CoV-2 (COVID-19) S1+S2 ECD (S-ECD) Recombinant Protein |
10-121 |
ProSci |
0.1 mg |
EUR 1186.8 |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity. |
SARS Protein Vector (Rat) (pPM-C-HA) |
PV303312 |
ABM |
500 ng |
EUR 723.6 |
SARS Protein Vector (Rat) (pPB-C-His) |
PV303310 |
ABM |
500 ng |
EUR 723.6 |
SARS Protein Vector (Rat) (pPB-N-His) |
PV303311 |
ABM |
500 ng |
EUR 723.6 |
SARS Protein Vector (Rat) (pPM-C-His) |
PV303313 |
ABM |
500 ng |
EUR 723.6 |
SARS Nucleocapsid Recombinant Protein |
10-213 |
ProSci |
0.1 mL |
EUR 752.1 |
Description: The nucleocapsid (N) protein of SARS-coronavirus (SARS-CoV) is the key protein for the formation of the helical nucleocapsid during virion assembly. The nucleocapsid (N) protein of SARS-CoV enters the host cell together with the viral RNA and interferes with several cellular processes. Some of these processes involve interactions between SARS-CoV N protein and host- cell proteins. It has also been demonstrated that the SARS-CoV N protein can bind to DNA in vitro. These interactions might have a role in the pathology of SARS. The N protein may be of potential value in vaccine development for specific prophylaxis and treatment against SARS. |
SARS Protein Vector (Human) (pPM-C-HA) |
PV036807 |
ABM |
500 ng |
EUR 394.8 |
SARS Protein Vector (Human) (pPM-C-HA) |
PV036811 |
ABM |
500 ng |
EUR 394.8 |
SARS Protein Vector (Mouse) (pPM-C-HA) |
PV226684 |
ABM |
500 ng |
EUR 723.6 |
SARS Protein Vector (Mouse) (pPM-C-HA) |
PV226688 |
ABM |
500 ng |
EUR 723.6 |
SARS Protein Vector (Human) (pPB-C-His) |
PV036805 |
ABM |
500 ng |
EUR 394.8 |
SARS Protein Vector (Human) (pPB-N-His) |
PV036806 |
ABM |
500 ng |
EUR 394.8 |
SARS Protein Vector (Human) (pPM-C-His) |
PV036808 |
ABM |
500 ng |
EUR 394.8 |
SARS Protein Vector (Human) (pPB-C-His) |
PV036809 |
ABM |
500 ng |
EUR 394.8 |
SARS Protein Vector (Human) (pPB-N-His) |
PV036810 |
ABM |
500 ng |
EUR 394.8 |
SARS Protein Vector (Human) (pPM-C-His) |
PV036812 |
ABM |
500 ng |
EUR 394.8 |
SARS Protein Vector (Mouse) (pPB-C-His) |
PV226682 |
ABM |
500 ng |
EUR 723.6 |
SARS Protein Vector (Mouse) (pPB-N-His) |
PV226683 |
ABM |
500 ng |
EUR 723.6 |
SARS Protein Vector (Mouse) (pPM-C-His) |
PV226685 |
ABM |
500 ng |
EUR 723.6 |
SARS Protein Vector (Mouse) (pPB-C-His) |
PV226686 |
ABM |
500 ng |
EUR 723.6 |
SARS Protein Vector (Mouse) (pPB-N-His) |
PV226687 |
ABM |
500 ng |
EUR 723.6 |
SARS Protein Vector (Mouse) (pPM-C-His) |
PV226689 |
ABM |
500 ng |
EUR 723.6 |
Recombinant SARS E1 gp Protein (aa 182-216) |
VAng-Lsx0070-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: SARS E1 glycoprotein (aa 182-216), recombinant protein from E. coli. |
SARS-CoV-2 Antibody (Nucleocapsid) |
RQ6297 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined. The structural proteins of SARS-CoV-2 include the envelope protein (E), spike or surface glycoprotein (S), membrane protein (M) and the nucleocapsid protein (N). The nucleocapsid phosphoprotein is a structural protein that binds to, protects the viral RNA genome and is involved in packaging the RNA into virus particles. The N protein has been suggested as an antiviral drug target. |
GENLISA™ Mouse SARS-CoV-2 IgG Antibody To Spike RBD Protein ELISA (Quantitative) |
KBVH015-13 |
Krishgen |
12 × 8 wells |
EUR 2002.5 |
GENLISA™ Mouse SARS-CoV-2 IgG Antibody To Spike S1 Protein ELISA (Quantitative) |
KBVH015-14 |
Krishgen |
12 × 8 wells |
EUR 2002.5 |
Recombinant SARS-CoV-2 S1+S2 ECD (S-ECD) Protein with His-Tag |
E80002-1 |
EpiGentek |
100 ul |
EUR 848.1 |
SARS Spike RBD Recombinant Protein |
10-211 |
ProSci |
0.1 mg |
EUR 651.3 |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS Polyclonal Antibody, HRP Conjugated |
A53978 |
EpiGentek |
-
EUR 684.66
-
EUR 302.50
-
EUR 423.50
|
|
SARS Polyclonal Antibody, FITC Conjugated |
A53979 |
EpiGentek |
-
EUR 684.66
-
EUR 302.50
-
EUR 423.50
|
|
SARS Polyclonal Antibody, Biotin Conjugated |
A53980 |
EpiGentek |
-
EUR 684.66
-
EUR 302.50
-
EUR 423.50
|
|
SARS-CoV-2 N Recombinant Antibody |
A73671 |
EpiGentek |
|
|
SARS-CoV-2 N Recombinant Antibody |
A73676 |
EpiGentek |
|
|
SARS-CoV-2 Antibody (NSP13 / Helicase) |
RQ6307 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
SARS Associated Coronavirus Matrix Protein |
20-abx260150 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1646.40
|
|
|
SARS Protease Substrate |
H-5982.0500 |
Bachem |
0.5mg |
EUR 356.4 |
Description: Sum Formula: C66H119N21O22S; CAS# [587886-51-9] net |
SARS Protease Substrate |
H-5982.1000 |
Bachem |
1.0mg |
EUR 618 |
Description: Sum Formula: C66H119N21O22S; CAS# [587886-51-9] net |
SARS-CoV-2 Spike Monoclonal Antibody |
A73664 |
EpiGentek |
|
|
Recombinant SARS Spike gp C Protein |
VAng-Lsx0072-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: SARS Spike glycoprotein C, recombinant protein from E. coli. |
SARS-CoV Nucleocapsid Recombinant Protein |
11-173 |
ProSci |
0.1 mg |
EUR 752.1 |
Description: Nucleocapsid (N) protein is the most abundant protein found in coronavirus. CoV N protein is a highly immunogenic phosphoprotein important for viral genome replication and modulation of cell signaling pathways. It was first identified by a research team while they were screening for ADP-ribosylated proteins during coronavirus (CoV) infection (Grunewald M. E., et al. 2017, Virology; 517: 62-68). The array of diverse functional activities accommodated in N protein makes it more than a structural protein but also an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, N protein of coronavirus is chosen as a diagnostic tool. |
SARS Coronavirus Mosaic Recombinant protein |
39-110 |
ProSci |
0.05 mg |
EUR 556.8 |
Description: SARS or severe acute respiratory syndrome is a lethal kind of pneumonia generated by coronavirus. Coronaviruses are a family of viruses that causes a mild respiratory tract infection is a large type of creatures such as humans, pigs, cows, mice, cats etc. up to this day, the origin of the coronavirus is still unknown. |
SARS Coronavirus Matrix Recombinant protein |
39-117 |
ProSci |
0.1 mg |
EUR 556.8 |
Description: SARS Coronavirus is an enveloped virus containing three outer structural proteins, namely the membrane (M), envelope (E), and spike (S) proteins. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. Accordingly, S-protein plays an important role in virus infection cycle and is the primary target of neutralizing antibodies. |
SARS-CoV-2 Antibody (NSP14 / Exonuclease) |
RQ6308 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
We show RhAd52 vaccines elicit sturdy SARS-CoV-2-specific antibody responses and defend in opposition to medical illness and viral replication within the lungs. Additional, binding and neutralizing antibody titers correlated with protecting efficacy. These information validate the MA10 mouse mannequin as a useful gizmo to display screen and research novel vaccine candidates, in addition to the event of RhAd52 vaccines for COVID-19.